Contineum Therapeutics Management
Management criteria checks 3/4
Contineum Therapeutics' CEO is Carmine Stengone, appointed in Oct 2018, has a tenure of 6.25 years. total yearly compensation is $2.32M, comprised of 22.3% salary and 77.7% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $159.91K. The average tenure of the management team and the board of directors is 4.3 years and 3 years respectively.
Key information
Carmine Stengone
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 22.3% |
| CEO tenure | 6.3yrs |
| CEO ownership | 0.05% |
| Management average tenure | 4.3yrs |
| Board average tenure | 3yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$29m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$447k |
| Dec 31 2023 | US$2m | US$516k | US$3m |
Compensation vs Market: Carmine's total compensation ($USD2.32M) is about average for companies of similar size in the US market ($USD2.26M).
Compensation vs Earnings: Insufficient data to compare Carmine's compensation with company performance.
CEO
Carmine Stengone (48 yo)
6.3yrs
Tenure
US$2,315,299
Compensation
Mr. Carmine N. Stengone, MS, MBA, serves as Chief Executive Officer, President & Director of Contineum Therapeutics, Inc. since October 2018 and served as its Chairman of the Board until March 2024. He ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$2.32m | 0.045% $ 159.9k | |
| Chief Financial Officer | 4.3yrs | US$1.03m | 0% $ 0 | |
| Chief Science Officer | 6.8yrs | US$1.79m | 0.67% $ 2.4m | |
| Senior Manager of Accounting | less than a year | no data | no data | |
| General Counsel & Corporate Secretary | less than a year | no data | no data | |
| Chief Medical Officer & Senior VP of Clinical Development | 5yrs | no data | 0.050% $ 176.3k | |
| Senior VP & Head of Research | no data | no data | no data | |
| Senior Director & Corporate Controller | 3.8yrs | no data | no data |
4.3yrs
Average Tenure
52yo
Average Age
Experienced Management: CTNM's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$2.32m | 0.045% $ 159.9k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Clinical Advisor | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Chairman of the Board | 3yrs | US$23.82k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$25.00k | 0% $ 0 | |
| Independent Director | 5.2yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
3.0yrs
Average Tenure
52yo
Average Age
Experienced Board: CTNM's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 00:08 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Contineum Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Jeff Hung | Morgan Stanley |
| Luke Davis | RBC Capital Markets |